Targeting biofilms and persisters of ESKAPE pathogens with P14KanS, a kanamycin peptide conjugate

Biochimica et Biophysica Acta - General Subjects

Volumn 1861, Issue 4, 2017, Pages 848-859

  Mohamed, Mohamed F ^a   Brezden, Anna ^b   Mohammad, Haroon ^a   Chmielewski, Jean ^b   Seleem, Mohamed N ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Anti inflammatory; Antimicrobial peptides; Biofilm; ESKAPE; Kanamycin; Persisters

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; COLISTIN; GENTAMICIN; INTERLEUKIN 6; KANAMYCIN; LINEZOLID; MELITTIN; NISIN; P 14KANS; RIFAMPICIN; TOBRAMYCIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; PEPTIDE;

ACINETOBACTER BAUMANNII; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BIOFILM; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DRUG STRUCTURE; ENTEROBACTER; ENTEROCOCCUS FAECIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; ANIMAL; BACTERIAL INFECTIONS; CELL LINE; CELL MEMBRANE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOFILMS; CAENORHABDITIS ELEGANS; CELL LINE; CELL MEMBRANE; HUMANS; KANAMYCIN; MICROBIAL SENSITIVITY TESTS; PEPTIDES;

EID: 85011004235     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2017.01.029     Document Type: Article

References (62)

1. [1] Peterson, L.R., Bad bugs, no drugs: no ESCAPE revisited. Clin. Infect. Dis. 49 (2009), 992–993.
2. [2] CDC, Antibiotic resistance threats in the United States. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf, 2013.
3. [3] Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., Scheld, M., Spellberg, B., Bartlett, J., Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48 (2009), 1–12.
4. [4] Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., Harbarth, S., Hindler, J.F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D.L., Rice, L.B., Stelling, J., Struelens, M.J., Vatopoulos, A., Weber, J.T., Monnet, D.L., Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18 (2012), 268–281.
5. [5] Correa, A., del Campo, R., Perenguez, M., Blanco, V.M., Rodríguez-Baños, M., Perez, F., Maya, J.J., Rojas, L., Cantón, R., Arias, C.A., Villegas, M.V., Dissemination of high-risk clones of extensively drug-resistant Pseudomonas aeruginosa in Colombia. Antimicrob. Agents Chemother. 59 (2015), 2421–2425.
6. [6] Wang, C.Y., Jerng, J.S., Chen, K.Y., Lee, L.N., Yu, C.J., Hsueh, P.R., Yang, P.C., Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes. Clin. Microbiol. Infect. 12 (2006), 63–68.
7. [7] Mulcahy, L.R., Burns, J.L., Lory, S., Lewis, K., Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J. Bacteriol. 192 (2010), 6191–6199.
8. [8] Hoiby, N., Ciofu, O., Bjarnsholt, T., Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 5 (2010), 1663–1674.
9. [9] Shakil, S., Khan, R., Zarrilli, R., Khan, A.U., Aminoglycosides versus bacteria—a description of the action, resistance mechanism, and nosocomial battleground. J. Biomed. Sci. 15 (2008), 5–14.
10. [10] Mingeot-Leclercq, M.P., Glupczynski, Y., Tulkens, P.M., Aminoglycosides: activity and resistance. Antimicrob. Agents Chemother. 43 (1999), 727–737.
11. [11] Vakulenko, S.B., Mobashery, S., Versatility of aminoglycosides and prospects for their future. Clin. Microbiol. Rev., 16, 2003, 430.
12. [12] Poole, K., Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49 (2005), 479–487.
13. [13] Kuriakose, J., Hernandez-Gordillo, V., Nepal, M., Brezden, A., Pozzi, V., Seleem, M.N., Chmielewski, J., Targeting intracellular pathogenic bacteria with unnatural proline-rich peptides: coupling antibacterial activity with macrophage penetration. Angew. Chem. Int. Ed. Engl. 52 (2013), 9664–9667.
14. [14] Brezden, A., Mohamed, M.F., Nepal, M., Harwood, J.S., Kuriakose, J., Seleem, M.N., Chmielewski, J., Dual targeting of intracellular pathogenic bacteria with a cleavable conjugate of kanamycin and an antibacterial cell-penetrating peptide. J. Am. Chem. Soc., 2016.
15. [15] CLSI, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow aerobically; Approved Standard M7-A7. 2007, CLSI, Wayne, PA.
16. [16] Yan, J., Wang, K., Dang, W., Chen, R., Xie, J., Zhang, B., Song, J., Wang, R., Two hits are better than one: membrane-active and DNA binding-related double-action mechanism of NK-18, a novel antimicrobial peptide derived from mammalian NK-lysin. Antimicrob. Agents Chemother. 57 (2013), 220–228.
17. [17] Nagant, C., Pitts, B., Nazmi, K., Vandenbranden, M., Bolscher, J.G., Stewart, P.S., Dehaye, J.P., Identification of peptides derived from the human antimicrobial peptide LL-37 active against biofilms formed by Pseudomonas aeruginosa using a library of truncated fragments. Antimicrob. Agents Chemother. 56 (2012), 5698–5708.
18. [18] Mohamed, M.F., Hamed, M.I., Panitch, A., Seleem, M.N., Targeting methicillin-resistant Staphylococcus aureus with short salt-resistant synthetic peptides. Antimicrob. Agents Chemother. 58 (2014), 4113–4122.
19. [19] Xiong, Y.Q., Mukhopadhyay, K., Yeaman, M.R., Adler-Moore, J., Bayer, A.S., Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus. Antimicrob. Agents Chemother. 49 (2005), 3114–3121.
20. [20] Mohamed, M.F., Hammac, G.K., Guptill, L., Seleem, M.N., Antibacterial activity of novel cationic peptides against clinical isolates of multi-drug resistant Staphylococcus pseudintermedius from infected dogs. PLoS One, 9, 2014, e116259.
21. [21] O'Toole, G.A., Microtiter dish biofilm formation assay. J. Vis. Exp., 2011.
22. [22] Mohamed, M.F., Abdelkhalek, A., Seleem, M.N., Evaluation of short synthetic antimicrobial peptides for treatment of drug-resistant and intracellular Staphylococcus aureus. Sci. Rep., 6, 2016, 29707.
23. [23] Srivastava, S., Ghosh, J.K., Introduction of a lysine residue promotes aggregation of temporin L in lipopolysaccharides and augmentation of its antiendotoxin property. Antimicrob. Agents Chemother. 57 (2013), 2457–2466.
24. [24] Mohamed, M.F., Seleem, M.N., Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) skin infection. Drug Des. Devel. Ther. 8 (2014), 1979–1983.
25. [25] Thangamani, S., Younis, W., Seleem, M.N., Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections. Sci. Rep., 5, 2015, 11596.
26. [26] Moy, T.I., Ball, A.R., Anklesaria, Z., Casadei, G., Lewis, K., Ausubel, F.M., Identification of novel antimicrobials using a live-animal infection model. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 10414–10419.
27. [27] Tampakakis, E., Okoli, I., Mylonakis, E., A C. elegans-based, whole animal, in vivo screen for the identification of antifungal compounds. Nat. Protoc., 3(2008), 1925-1931.
28. [28] Moskowitz, S.M., Brannon, M.K., Dasgupta, N., Pier, M., Sgambati, N., Miller, A.K., Selgrade, S.E., Miller, S.I., Denton, M., Conway, S.P., Johansen, H.K., Hoiby, N., PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients. Antimicrob. Agents Chemother. 56 (2012), 1019–1030.
29. [29] Falagas, M.E., Kasiakou, S.K., Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40 (2005), 1333–1341.
30. [30] Liu, Y.-Y., Wang, Y., Walsh, T.R., Yi, L.-X., Zhang, R., Spencer, J., Doi, Y., Tian, G., Dong, B., Huang, X., Yu, L.-F., Gu, D., Ren, H., Chen, X., Lv, L., He, D., Zhou, H., Liang, Z., Liu, J.-H., Shen, J., Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis., 2015.
31. [31] Koo, S.P., Bayer, A.S., Yeaman, M.R., Diversity in antistaphylococcal mechanisms among membrane-targeting antimicrobial peptides. Infect. Immun. 69 (2001), 4916–4922.
32. [32] Alder, J., Eisenstein, B., The advantage of bactericidal drugs in the treatment of infection. Curr. Infect. Dis. Rep. 6 (2004), 251–253.
33. [33] Conlon, B.P., Nakayasu, E.S., Fleck, L.E., LaFleur, M.D., Isabella, V.M., Coleman, K., Leonard, S.N., Smith, R.D., Adkins, J.N., Lewis, K., Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503 (2013), 365–370.
34. [34] Lechner, S., Lewis, K., Bertram, R., Staphylococcus aureus persisters tolerant to bactericidal antibiotics. J. Mol. Microbiol. Biotechnol. 22 (2012), 235–244.
35. [35] Keren, I., Kaldalu, N., Spoering, A., Wang, Y., Lewis, K., Persister cells and tolerance to antimicrobials. FEMS Microbiol. Lett. 230 (2004), 13–18.
36. [36] Hurdle, J.G., O'Neill, A.J., Chopra, I., Lee, R.E., Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat. Rev. Microbiol. 9 (2011), 62–75.
37. [37] Deslouches, B., Steckbeck, J.D., Craigo, J.K., Doi, Y., Mietzner, T.A., Montelaro, R.C., Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens. Antimicrob. Agents Chemother. 57 (2013), 2511–2521.
38. [38] Ong, Z.Y., Cheng, J., Huang, Y., Xu, K., Ji, Z., Fan, W., Yang, Y.Y., Effect of stereochemistry, chain length and sequence pattern on antimicrobial properties of short synthetic beta-sheet forming peptide amphiphiles. Biomaterials 35 (2014), 1315–1325.
39. [39] Costerton, J.W., Lewandowski, Z., Caldwell, D.E., Korber, D.R., Lappin-Scott, H.M., Microbial biofilms. Annu. Rev. Microbiol. 49 (1995), 711–745.
40. [40] Mah, T.F., O'Toole, G.A., Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9 (2001), 34–39.
41. [41] Hoiby, N., Bjarnsholt, T., Givskov, M., Molin, S., Ciofu, O., Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents 35 (2010), 322–332.
42. [42] Christensen, G.D., Bisno, A.L., Parisi, J.T., McLaughlin, B., Hester, M.G., Luther, R.W., Nosocomial septicemia due to multiply antibiotic-resistant Staphylococcus epidermidis. Ann. Intern. Med. 96 (1982), 1–10.
43. [43] Kaplan, J.B., Ragunath, C., Velliyagounder, K., Fine, D.H., Ramasubbu, N., Enzymatic detachment of Staphylococcus epidermidis biofilms. Antimicrob. Agents Chemother. 48 (2004), 2633–2636.
44. [44] Singh, R., Ray, P., Das, A., Sharma, M., Penetration of antibiotics through Staphylococcus aureus and Staphylococcus epidermidis biofilms. J. Antimicrob. Chemother. 65 (2010), 1955–1958.
45. [45] Williams, D.L., Bloebaum, R.D., Observing the biofilm matrix of Staphylococcus epidermidis ATCC 35984 grown using the CDC biofilm reactor. Microsc. Microanal. 16 (2010), 143–152.
46. [46] Zasloff, M., Antimicrobial peptides of multicellular organisms. Nature 415 (2002), 389–395.
47. [47] Soong, G., Paulino, F., Wachtel, S., Parker, D., Wickersham, M., Zhang, D., Brown, A., Lauren, C., Dowd, M., West, E., Horst, B., Planet, P., Prince, A., Methicillin-resistant Staphylococcus aureus adaptation to human keratinocytes. MBio, 6, 2015.
48. [48] von Eiff, C., Becker, K., Metze, D., Lubritz, G., Hockmann, J., Schwarz, T., Peters, G., Intracellular persistence of Staphylococcus aureus small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with Darier's disease. Clin. Infect. Dis. 32 (2001), 1643–1647.
49. [49] Brouillette, E., Grondin, G., Shkreta, L., Lacasse, P., Talbot, B.G., In vivo and in vitro demonstration that Staphylococcus aureus is an intracellular pathogen in the presence or absence of fibronectin-binding proteins. Microb. Pathog. 35 (2003), 159–168.
50. [50] Buyck, J.M., Tulkens, P.M., Van Bambeke, F., Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes. Antimicrob. Agents Chemother. 57 (2013), 2310–2318.
51. [51] Mempel, M., Schnopp, C., Hojka, M., Fesq, H., Weidinger, S., Schaller, M., Korting, H.C., Ring, J., Abeck, D., Invasion of human keratinocytes by Staphylococcus aureus and intracellular bacterial persistence represent haemolysin-independent virulence mechanisms that are followed by features of necrotic and apoptotic keratinocyte cell death. Br. J. Dermatol. 146 (2002), 943–951.
52. [52] Lyle, N.H., Pena, O.M., Boyd, J.H., Hancock, R.E., Barriers to the effective treatment of sepsis: antimicrobial agents, sepsis definitions, and host-directed therapies. Ann. N. Y. Acad. Sci. 1323 (2014), 101–114.
53. [53] Cohen, J., The immunopathogenesis of sepsis. Nature 420 (2002), 885–891.
54. [54] Yeaman, M.R., Yount, N.Y., Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55 (2003), 27–55.
55. [55] Hancock, R.E., Sahl, H.G., Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24 (2006), 1551–1557.
56. [56] Uccelletti, D., Zanni, E., Marcellini, L., Palleschi, C., Barra, D., Mangoni, M.L., Anti-Pseudomonas activity of frog skin antimicrobial peptides in a Caenorhabditis elegans infection model: a plausible mode of action in vitro and in vivo. Antimicrob. Agents Chemother. 54 (2010), 3853–3860.
57. [57] Jayamani, E., Rajamuthiah, R., Larkins-Ford, J., Fuchs, B.B., Conery, A.L., Vilcinskas, A., Ausubel, F.M., Mylonakis, E., Insect-derived cecropins display activity against Acinetobacter baumannii in a whole-animal high-throughput Caenorhabditis elegans model. Antimicrob. Agents Chemother. 59 (2015), 1728–1737.
58. [58] de la Fuente-Nunez, C., Reffuveille, F., Mansour, S.C., Reckseidler-Zenteno, S.L., Hernandez, D., Brackman, G., Coenye, T., Hancock, R.E., D-enantiomeric peptides that eradicate wild-type and multidrug-resistant biofilms and protect against lethal Pseudomonas aeruginosa infections. Chem. Biol. 22 (2015), 196–205.
59. [59] Begun, J., Gaiani, J.M., Rohde, H., Mack, D., Calderwood, S.B., Ausubel, F.M., Sifri, C.D., Staphylococcal biofilm exopolysaccharide protects against Caenorhabditis elegans immune defenses. PLoS Pathog., 3, 2007, e57.
60. [60] Begun, J., Sifri, C.D., Goldman, S., Calderwood, S.B., Ausubel, F.M., Staphylococcus aureus virulence factors identified by using a high-throughput Caenorhabditis elegans-killing model. Infect. Immun. 73 (2005), 872–877.
61. [61] Edwards, S., Kjellerup, B.V., Exploring the applications of invertebrate host-pathogen models for in vivo biofilm infections. FEMS Immunol. Med. Microbiol. 65 (2012), 205–214.
62. [62] Patel, L.N., Wang, J., Kim, K.J., Borok, Z., Crandall, E.D., Shen, W.C., Conjugation with cationic cell-penetrating peptide increases pulmonary absorption of insulin. Mol. Pharm. 6 (2009), 492–503.